March 3, 2005Journal of Antimicrobial Chemotherapy

Novel (biphenyloxy)propylisoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication

View Full Paper

Ask AI

Bookmark

Population

HeLa cells infected with pleconaril-resistant coxsackievirus B3 strain Nancy, human rhinovirus 2 and 14, and…

Design

Preclinical

Authors

VMVadim MakarovNational University of Science and Technology OROlga RiabovaRussian Academy of Sciences ВГВ. Г. ГраникScientific Research Institute of Organic Intermediates and Dyes

Discussion

Member takes

Implication

May support preclinical antiviral development; leaves open clinical utility pending in vivo and human studies.

Structured PICO

Population

HeLa cells infected with pleconaril-resistant coxsackievirus B3 (CVB3) strain Nancy, human rhinovirus 2 (HRV-2) and 14 (HRV-14), and pleconaril-sensitive human isolate CVB3 97-927

Intervention

Novel [(biphenyloxy)propyl]isoxazole derivatives

Outcome

Antiviral activity measured by selectivity index (SI), defined as the ratio of 50% cytotoxic concentration to 50% inhibitory concentrationsurrogate

Novel [(biphenyloxy)propyl]isoxazole derivatives demonstrate promising in vitro antiviral activity against human rhinovirus 2 and coxsackievirus B3.

Cite This Study

Makarov et al. (2005) studied this question.

synapsesocial.com/papers/6a87cd750112b7b407bb50d8 https://doi.org/10.1093/jac/dki055

View Full Paper

Ask AI

Bookmark

Novel (biphenyloxy)propylisoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Novel (biphenyloxy)propylisoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider